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Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón 
Puerto Rico 
1. Introduction  
Persons infected with the human immunodeficiency virus (HIV) have an elevated risk for 
the development of Cancer. Some of the malignant processes are intrinsic to the 
immunological impact of the HIV infection; others are more often related to the risk 
scenarios associated to the viral inoculum and subsequent development of the infection. In 
general terms, malignant transformation is fundamentally caused by genetic alterations to 
individual cells, which allow the presence of the disorganized autonomous growth of cells 
and the development of properties associated to the survival of the cancer cells. Properties 
associated to successful growth of the cancer include the capacity for relative autonomous 
growth, evasion of the normal regulatory process present within bodies, capacity of tissue 
invasion, spread to other organs and disruption of the normal organ homeostasis. 
Predisposing conditions that lead to an increased risk for the malignant transformation 
include chronic inflammatory states, congenital or acquired genetic mutations, autoimmune 
diseases, and exposure to environmental factors. The presence of HIV infection, particularly 
in the context of a deteriorated immune system is associated to an increased risk for the 
development of Kaposi’s sarcoma, high-grade non-Hodgkin’s lymphomas, central nervous 
system lymphoma and invasive uterine cervical cancer. Collectively these entities may be 
the initial manifestation of HIV infection and are intimately associated to the deteriorated 
immune system associated to the infection. As such they are considered AIDS defining 
conditions. The spectrum of HIV associated malignant disorders also includes non-AIDS 
defining cancers. Non-AIDS defining malignancies are often seen in patients who are at 
younger age than usual, are associated to a more aggressive behavior and tend to be 
diagnosed at a more advanced stage. The most common non-AIDS defining malignancies 
include Hodgkin’s lymphomas, non-small cell lung cancer, head and neck cancer, ano-
genital cancer,  hepatic cancer and possibly multiple myeloma. The role of the HIV virus in 
triggering the malignant transformation of cells appears to be a direct effect by promoting 
cancer growth, and indirect in others by disrupting the human regulatory symbiosis 
provided by the immune system.  The introduction of multiple spectrum antiretroviral 
therapy (ART) and the availability of highly active antiretroviral therapy (HAART) have 
caused a dramatic improvement in the immunological function of infected subjects with an 
associated increment in the overall survival of these patients. The use of HAART has been 
intimately associated to a dramatic decrease in not only AIDS defining opportunistic 
infections but in some of the AIDS defining tumors particularly Kaposi’s sarcoma and non 
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Hodgkin’s lymphomas.  Nevertheless changes in the incidence of invasive cervical 
carcinoma and non-AIDS defining cancers have not been so remarkable.  HIV infection has 
become a chronic condition associated to a longer lifespan of patients and the introduction 
of an evolving list of co-morbid conditions, including cancer. Under this scenario, 
understanding the trends on cancer development in this population of patients has become 
of marked importance, since they represent the next boundary that is limiting the survival of 
the HIV infected patient. In this chapter we describe the changing trends in the incidence of 
malignant disorders which affect the HIV infected patients with a particular emphasis on 
the role of HAART in the expression of these malignant conditions (Bedimo et al, 2004; 
Bonne et al., 2008; Bower et al, 2006; Caceres et al., 2010; Crum-Clanflone et al, 2009; Engels 
et al., 2008; Gurlich et al., 2002; Long et al., 2008;Mitsuyasy et al., 2011; Newcomb-Fernandez 
et al., 2003; Patel et al., 2008; Simard et al., 2010) .  
2. Cancer 
Hereditary or acquired genetic mutations, autoimmune disorders, and exposure to certain 
environmental agents may singly or in a combined synergistic fashion, predispose to the 
development of neoplasms. The role of HIV in inducing the malignant transformation of 
cells appears to be an indirect effect by disrupting the human immune regulatory process. 
Immunological deficiency induced by HIV causes a progressive impairment of the cellular 
immunity responsible for the control of viral growth and the immune recognition against 
virus-infected or altered cells in the different stages of malignant transformation. HIV 
induced cytokine deregulation disrupts the host’s capacity to control oncogenic viral 
reactivation and replication, ultimately increasing the risk for malignant transformation. 
Oncogenic viruses, including the Ebstein-Barr virus (EBV), human herpesvirus 8 (HHV 8), 
certain subtypes of the human papilloma virus, hepatitis B virus (HBV), and hepatitis C 
virus (HCV) have all been causally related to the increasing prevalence of cancer 
development in these patients. In addition the presence of certain risky lifestyle behaviors 
often present in the HIV infected patients such as smoking, alcohol use, use of illegal drugs 
and sexual promiscuity may contribute and accelerate the risk of malignant transformation 
in these subjects. HIV associated severe immunosuppression may be interrupted or partially 
restored with the use of ART. Improvement or partial restoration of the cell-mediated 
immunity and the suppression of the HIV viral load will not only improve the patients’ 
immunological status but will improve the overall clinical status with an improvement in 
overall survival. An increment in the survival of the HIV infected patient leads to an aging 
patient cohort with a higher likelihood of oncogenic viruses exposure. These elements alter 
the clinical course of the HIV infection with the development of new morbidity patterns 
such as altered toxicity profiles of medications, development of metabolic disorders, long 
lasting co-infections (including HPV, HHV, HCV, HBV and EBV), development of an 
increased risk of cardiovascular diseases and non-AIDS defining neoplasms. Even though, 
for many of the tumors described in this chapter, there are no specific prevention guidelines, 
other than the need to diagnose early and institute therapy as early as possible.  
2.1 AIDS defining malignances 
Kaposi’s sarcoma, high-grade non-Hodgkin’s lymphomas, including the high-grade 
immunoblastic or diffuse large cell lymphoma, the small noncleaved (Burkitt, Burkitt-like or 
non-Burkitt) lymphoma, primary central nervous system lymphoma (PCNSL), and invasive 
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cervical cancer are neoplasms included as AIDS defining conditions. With the introduction 
of HAART the spectrum of these cancers has changed, with a dramatic reduction in the 
incidence of Kaposi’s sarcoma and non-Hodgkin’s lymphomas.  However, the impact of 
HAART in the invasive cervical cancer had not been significant. It is relevant to mention 
that in spite of HAART, the risk for AIDS defining cancers continues to be significantly 
higher as compared to the non HIV infected general population (Simard et al., 2010).  
2.1.1 Kaposi’s sarcoma  
Kaposi’s sarcoma is an angio-proliferative disease characterized by tumors composed of 
new blood vessel (angiogenesis), endothelial spindle cell growth, inflammatory cell 
infiltration and edema. Kaposi’s sarcoma is classified in four epidemiologic variants: the 
classic, the African endemic, the iatrogenic, and the epidemic AIDS-related.  The clinical 
manifestation of this sarcoma in patients with AIDS is variable but usually presents as a 
multiple, small, innocuous pigmented cutaneous or oral-pharyngeal lesions. These may 
grow and spread causing symptom-producing visceral disease.  Alternatively it may 
develop in a multifocal fashion in several sites at the same time. In both cases it may result 
in a life-threatening process with the need of aggressive therapy.   
2.1.1.1 Pathophysiology 
The pathogenesis of the condition was clarified in 1994 when human herpes virus-8 (HHV-
8) also known as Kaposi’s sarcoma -associated herpes virus (KSHV) was described and 
detected in all forms of Kaposi’s sarcoma. HHV-8 is a transmissible DNA virus with a 
seroprevalence in the United States between 1%-5%. The pathogenesis of AIDS related 
Kaposi’s sarcoma is multifactorial and includes HHV-8 infection, HIV induced cytokine 
malfunction, and stimulation transactivating transduction (TAT) protein by HIV. HHV-8 is 
an oncogenic virus transmitted both sexually and through body fluids such as saliva and 
blood, which encodes a cell protein involved in signal transduction, cell cycle regulation and 
inhibition of apoptosis. HHV-8 is critical in the pathogenesis of this AIDS related sarcoma, 
but by itself is not sufficient to cause the cancer. The risk of this cancer is directly related to 
the degree of immune suppression in the host and can remain in a latent phase for many 
years. The interaction between HIV-TAT protein and the immune suppressed state of the 
host allows the activation of the virus resulting in an abnormal inflammatory response and 
the promotion of angiogenesis by inducing lymphatic reprogramming of the vascular 
endothelium. 
2.1.1.2 Clinical manifestation and diagnosis 
The clinical presentation of Kaposi’s sarcoma ranges from irregular reddish discrete lesions 
to violaceous or brown nodules, macules, patches, or plaques. The lesions are usually 
painless, do not blanch under pressure and may be associated with edema, lymph node or 
visceral involvement. Pathologic confirmation is required to establish a diagnosis of 
Kaposi’s sarcoma since bacillary angiomatosis can mimic this malignancy even for the 
seasoned clinician. The lesions may occur in any part of the body, including the face, chest, 
oral mucosa, penis or scrotum, rectum, and conjunctiva. The oral cavity can be extensively 
involved resulting in airway obstruction. The gastrointestinal tract is a common site of the 
disease. These lesions are often asymptomatic but can be associated with abdominal pain, 
gastro-intestinal bleeding, diarrhea, abdominal cramps, and weight loss. Visceral 
involvement occurs in over 50% of the cases.  Pulmonary involvement is the second most 
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common extra-cutaneous location and may present with life threatening manifestations. 
Pulmonary involvement is often associated with obstructive respiratory symptoms, 
hemoptysis and chest pain. The clinical course of this sarcoma is variable with the presence 
of slowly progressive lesions over the course of many years, or it may have a rapid   
progression over a course of weeks or months. The external appearance of the cutaneous 
lesions may lead to emotional distress and stigmatization. The use of corticosteroid therapy 
has been associated with the induction or exacerbation of this cancer in the context of the 
HIV infected individual (Bellan et al, 2003; Dezube, 2007). 
2.1.1.3 Therapy 
The decision to institute therapy needs to consider the extent, location and rate of tumor 
growth as well as the patient’s symptoms, and immune system condition. Optimization of 
HAART therapy is critical in all patients with Kaposi’s sarcoma since this tumor is 
intrinsically linked to the degree of immunosuppression and the fact that up to 91% of 
lesions regress with HAART. Immune reconstitution is a primordial therapeutic goal in 
every patient. For limited skin lesions, the application of topical therapy with liquid 
nitrogen, vinblastine or retinoic acid may be appropriate. External beam radiotherapy is also 
an option in certain cases. Interferon-α is an immunomodulator with antiviral and anti-
angiogenic effect that has been used with some success in patients with the cutanous form of 
the disease. Its widespread use has been hampered by its toxicity profile, which is often 
moderate to severe in nature. For patients with edema, extensive mucocutaneous disease, or 
symptomatic pulmonary or gastrointestinal involvement, the administration of systemic 
chemotherapy is recommended. Several single agent drugs are active in this AIDS related 
sarcoma. These include vincristine, vinblastine, etoposide, anthracyclines, bleomycin and 
taxol with an overall response rate of 76%. The administration of combination 
chemotherapy has been utilized since early 1991 for rapidly progressive mucocutaneous or 
visceral disease. The most common drug combination has been doxorubicin, bleomycin and 
vincristine (ABV) or bleomycin and vincristine (BV). The use of liposomal anthracyclines is 
currently considered the optimal first line therapy for the treatment of advanced Kaposi’s 
sarcoma. This single agent therapy has been reported to have similar or improved response 
rates to other drugs but less toxicity. Paclitaxel (taxol) is the most recent introduction to the 
systemic chemotherapeutic agents available for these patients. Its use is often prescribed as 
second line therapy for patients with refractory disease. The response rate with paclitaxel is 
between 59-71%.  Additional drugs that have variable rate of success in this disease include 
inhibitors of angiogenesis such as thalidomide, inhibitors of tyrosine kinase or mammalian 
rapamycin pathways such as imatinib and sunitinib. The response rate after standard 
chemotherapy is usually very good, but they tend to be short lasting. The high incidence of 
opportunistic infections associated to the administration of chemotherapy along with the 
chemotherapy associated cytopenias, are major issues in the management of these patients 
(Berretta et al, 2003; Dezube, 2007).  
2.1.1.4 Epidemiology  
Kaposi’s sarcoma is a rare condition in the HIV negative population; however, it is the most 
common malignancy associated with HIV infection. This cancer had been more often 
detected in HIV-positive persons with more advanced immunosuppression (CD4+ T 
lymphocyte counts of <200 cells/µL), and especially in men who have sex with men (MSM). 
Among MSM the transition of the HHV-8 is predominately by deep kissing. In these 
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individuals the HHV-8 prevalence that is associated with their number of homosexual 
partners is considerably greater when compare to the other HIV risk behavior groups. The 
probability of developing Kaposi’s sarcoma in HIV infected persons who are infected with 
HHV-8 is significantly high. The overall incidence of this cancer was as high as 20% among 
patients with AIDS before the advent of effective ART. However the incidence decreases 
dramatically since the introduction of HAART and remains low (Bedimo et al., 2004). The 
HIV/AIDS Cancer Match Study of 263.254 AIDS cases followed in 15 States of the United 
States between 1980 and 2008 reveals a significant reduction of this sarcoma incidence of 
80% (RR, 0.2: 95% CI, 0.2%-0,2%) in the HAART era (Simard et al, 2010). This study concord 
with previous studies performed in United States and Puerto Rican’s HIV cohorts that 
reported a significant reduction in the incidence or prevalence of this cancer after the 
antiretroviral therapies era (Engel et al., 2008; Crum-Cianflone et al., 2009; Mayor et al., 
2008b). Despite the significant incidence reduction of Kaposi’s sarcoma the risk of this 
cancer in HIV infected persons remains significantly elevated in the HAART era, when 
compare to the general population (Simard et al., 2010; Engels et al., 2008; Patel et al., 2008). 
2.1.1.5 Prevention 
Routine screening for HHV-8 by PCR or serologic testing is not indicated for HIV-infected 
persons. It has been advocated that HAART therapy will reduce the incidence of Kaposi’s 
sarcoma by improving the immunological state and preventing tumor growth. Thus 
opportune antiretroviral therapy is an effective preventive strategy for patients who qualify.  
2.1.2 Non Hodgkin’s lymphoma 
Non-Hodgkin’s lymphomas represent a diverse group of malignant conditions of the 
immune system. These tumors are 60-100 times more common in the HIV infected patient as 
compared to the general population. There are three histological subtypes that are 
responsible for the majority of non-Hodgkin’s lymphomas diagnosed in HIV patients and 
they include small non-cleaved lymphomas (Burkitts and non Burkitts like), high grade 
large cell, and the immunoblastic lymphomas, commonly present with the brain as primary 
site.  With the institution of HAART the incidence of lymphomas in these patients has 
decreased but the decrement is much less as compared to the other AIDS defining 
conditions. The risk of developing non-Hodgkin’s lymphomas has decreased from 1,226 to 
306 per 100,000 person years after the introduction of HARRT (Simard et al., 2010).  
However, the prevalence of these lymphomas in HIV persons after HAART remains high 
when compare to HIV negative population (Engels et al., 2008; Simard et al., 2010; Bierman 
et al., 2004; Doweiko, 2007b). 
2.1.2.1 Pathophysiology  
The pathogenesis of AIDS related non-Hodgkin’s lymphomas are fundamentally related to 
repeated stimulation and proliferation of B cells in the setting of a T–cell immunodeficiency. 
This results in the loss of immune surveillance and the continued proliferation of aberrant B 
cell clones. Etiologic agents implicated in the abnormal B cell proliferative response include 
HIV, Ebstein Barr virus and other infections.  The presence of HIV induces the expression of 
cytokines (IL-6, IL-10 and TNF-α), which also contribute to B cell activation and 
proliferation. The process of B cell expansion results in lymph node enlargement and is 
usually accompanied by polyclonal hypergammaglobulinemia. The enhanced proliferative 
response of B cells increases the opportunity of genetic error, which may result in the 
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dysregulation of suppressor genes (p53) and/or activation of proto-oncogenes (c-myc, BCL-
6 or ras). The majority of AIDS-related non-Hodgkin’s lymphomas (75%) carry alterations in 
at least one proto-oncogene and more than 90% have alterations in at least one of the 
suppression genes.  The presence of activation cytokines such as IL-6 and IL-10 contribute to 
the chronic B cell stimulation resulting in continued growth. Specifically, IL-6 activity that 
increases early in the course of HIV infection is predictive of the likelihood of lymphoma 
developing over time. IL10 is an autocrine growth factor for lymphoma and an inhibitor of 
cellular immune response. Elevated levels of IL-10 are associated to a worse prognosis in 
AIDS related non-Hodgkin’s lymphomas (Bellan et al, 2003; Doweiko, 2007b).  
2.1.2.2 Clinical manifestation and diagnosis 
The presence of constitutional symptoms (fever, weight loss and night sweats) is seen in 80-
90% of patients with AIDS-related non-Hodgkin’s lymphomas. It is vital to exclude the 
presence of opportunistic infections in these patients prior to instituting antineoplastic 
therapy. Most patients initially present with advanced stage of lymphoma with 80% 
presenting as a stage IV. Common sites of extra-nodal involvement include central nervous 
system (30%), gastrointestinal tract (25%), bone marrow (25%) and liver (17%). Nevertheless 
any site of the body may be involved with AIDS-related non-Hodgkin’s lymphomas 
including the rectum, soft tissue, oral cavity, lungs and heart. Bone marrow and 
leptomeningeal involvement are more often associated with small, non cleaved (Burkitt-like) 
lymphoma. Patients with gastrointestinal involvement may present with pain, weight loss, 
bleeding, obstruction and perforation in 40% of the cases. The prognosis of this group of 
patients tends to be better; they respond very well to therapy and have a longer survival. 
Patients with primary central nervous system lymphoma often present with focal 
neurologic deficits, seizures, and or altered mental status. A diagnosis of non-Hodgkin’s 
lymphomas requires histological confirmation by biopsy with immunephenotypic and 
molecular rearrangement studies. A complete staging evaluation must be done once a 
diagnosis is made utilizing body imaging studies of the brain, bone marrow aspiration 
and biopsy, liver function studies and spinal fluids analysis if clinically indicated. The 
presence of Ebstein Barr virus DNA in cerebrospinal fluid by polymerase chain reaction is 
a high specific and sensitive diagnosis criterion for primary central nervous system 
lymphoma. 
The majority of in HIV related non-Hodgkin’s lymphomas are associated with one of three 
histological subtypes mentioned above. The presence of small non-cleaved lymphomas 
(Burkitts and non Burkitts like) accounts for 40% of them and is usually seen in patients 
with a higher CD4 counts than other types. They often express an abnormal p53 and c-myc 
or ras oncogenes. The high-grade large cell histology is seen in 40% of patients and is 
associated with an abnormal expression of BCL-6 in 40% of the cases. One of the particular 
presentations of this histology is primary effusion lymphoma. Primary effusion lymphoma 
occurs as a late manifestation of HIV infection and has a poor clinical outcome and a shorter 
6 months survival as compared to other sites of this histology. This high-grade lymphoma 
originates in the pleura, pericardium, peritoneum, serosal surface or rarely in the meninges. 
The etiologic cause of this lymphoma is related to herpes virus-8 infection of the tumor 
clone. A previous history of Kaposi sarcoma increases the risk of developing primary 
effusion lymphoma, and often genomic material containing the imprint of KSHV/HHV8 
genes is found in the malignant clone of cells. The remaining 30% of AIDS-related non-
Hodgkin’s lymphomas are inmunoblastic plasmocytoid lymphomas and are considered to 
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be related to EBV infection. The most important presentation of this histology is the primary 
central nervous system lymphoma, which accounts for 20% of all AIDS related lymphomas. 
This histology is seen in advanced stage AIDS with CD4 cell counts below 30 cells/mm, and 
they rarely occur outside the brain. The incidence of primary central nervous system 
lymphoma has decreased with the introduction of HAART but remains a disease with poor 
outcome. This type of lymphomas is the second most common brain space-occupying lesion 
in patients with AIDS after toxoplasmosis. The most common location for primary central 
nervous system lymphomas is cerebral hemispheres, following by basal ganglia, cerebellum, 
and brain stem, with less than 10% involving posterior fossa. Unlike primary central 
nervous system lymphoma in the general population, these tumors can have ring-
enhancement due to their rapid growth. The tumors usually measure at least 3 cm and may 
present with central necrosis.  Management of this primary lymphoma consists of radiation 
therapy, the use of corticosteroids and alkylating agents. This therapy will increase length of 
survival but they rarely induce lasting remissions (Bierman et al., 2004; Doweiko, 2007b).  
2.1.2.3 Treatment 
The mainstay of therapy for patients with AIDS related non-Hodgkin’s lymphomas are 
systemic chemotherapy. The common used regimens include R-CHOP, m-BACOP, EPOCH 
although no regimen appears superior to the other. System prophylaxis with intrathecal 
cytarabine (ARA-C 50 mg) or methotrexate (10-12 mg) every week for four weeks has been 
shown to reduce central nervous system relapse in the high risk group of patients. The 
major complication of chemotherapy is myelosuppression with its associated morbidities. 
Several studies have shown that co-administration with hematopoietic growth factors may 
enhance the chemotherapy toleration. In addition, prophylaxis with trimethropim/sulfa, 
azithromycin, fluconazole, ciprofloxacin, and valgancyclovir can reduce the risk of infection 
during intensive chemotherapy regimen. Refractory or relapse systemic lymphomas have 
a very poor prognosis with no satisfactory second line therapy available. An important 
factor in the management of AIDS related non-Hodgkin’s lymphomas is the use of 
HAART to reduce the viral load and enhance the immune system management of the 
malignant clone.  
2.1.2.4 Epidemiology 
In the United States, 3% of the AIDS cases present with lymphoma. The major risk factors 
include older age, magnitude and duration of the immunosuppression, no prior HAART 
use or insufficient immunologic or virologic response to HAART.  The types of risky 
practices associated to HIV infections are not associated to the presence of lymphoma. AIDS 
related non-Hodgkin’s lymphomas are seen more frequent in men than in women and is 
seen more often in whites than in blacks. The standardized incidence rate of AIDS 
associated lymphoma is significantly higher than in the general population (Grulich et al., 
2007). Most of the AIDS related non-Hodgkin’s lymphomas (75%) have advanced HIV 
disease, however 25 % of patients develop the disease when the viral load is undetectable. 
Different studies had reported a significant reduction in the incidence of these lymphomas 
with the availability of effective antiretroviral therapies, particularly HAART (Bedimo et al., 
2004). For example the HIV/AIDS Cancer Match Study of Simard et al, reported a 70% 
decline in their incidence (RR, 0.3: 95% CI, 0.2%-0.3%) as compared to the pre-HAART era 
(Simard, et al., 2010).  The study found significant reduction in the diffuse large B cell and in 
the CNS Hodgkin’s lymphomas NHL, but no differences were seen in the Burkitt-like 
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histological lymphomas. Similar findings were documented in the other United States and 
Puerto Rican AIDS cohorts (Engels et al., 2008; Mayor et al., 2008b). Despite this significant 
reduction, non-Hodgkin’s lymphomas risk remained significantly higher in HIV infected 
persons after HAART when compared to the general population as reported by Patle et al, 
Simard et al. and Engels et al.  
2.1.2.5 Prevention 
The risk of developing non-Hodgkin’s lymphoma is directly proportional to the disruption 
of the immune system. The appropriate and opportune use of antiretroviral therapy 
(HAART) is necessary to reduce this risk.  There are no specific prevention guidelines, other 
than the need to diagnose early and institute therapy as early as possible.  
2.1.3 Invasive cervical cancer 
Cervical cancer is a malignant proliferation of the squamous epithelium of the ectocervix 
causing squamous cell carcinoma. Malignant proliferation of the glandular lining of the 
endocervix carries histology of adenocarcinoma.  More than 95% of cervical tumors have 
squamous cell histology and infection with the Human papilloma virus (HPV) is a necessary 
factor for the malignant transformation in the majority of these patients. Several subtypes of 
the HPV have delineated as responsible for the development of cervical dysplasia, which 
represents the usual histological antecedent to invasive tumors of the ectocervix. A higher 
incidence of HPV-related dysplasia, more advanced stages of cervical dysplasia and 
refractoriness to standard therapy is characteristic of this disease in females who also have 
HIV infection. The similarities in risk profiles and transmission modes between HIV and 
HPV explain the common and widespread presence of HPV in this group of patients. The 
higher risk of developing cervical dysplasia in HIV infected women initially promoted the 
inclusion of cervical cancer as one of the AIDS defining condition in 1993. The presence of 
HIV associated immunosuppression contributes to an impaired HPV clearance, facilitating 
progression of early stage to more advanced forms of dysplasia. The role of HIV in the 
ultimate transformation to cervical carcinoma is not so clearly defined. Cervical cancer is a 
tumor, which can be prevented and clearly curable if diagnosed at an early stage. 
Aggressive prevention strategies have significantly decreased the incidence and prevalence 
of this tumor in developed countries (Molpus &Jone, 2004; Powrie & Cu-Uvin, 2007). 
2.1.3.1 Pathophysiology  
The majority of squamous cell carcinomas of the cervix are preceded by a premalignant 
epithelial dysplasia known as cervical intraepithelial neoplasia and squamous intraepithelial 
lesions. These lesions slowly progress to the invasive form of cervical cancer. HPV infection 
has an important role in the genesis of this dysplasia and in the progression to an invasive 
state. This is in large part due to the chronic inflammatory insult induced by this oncogenic 
virus. HPV infection is the most common sexually transmitted infection in the US with an 
increasing prevalence seen among HIV infected individuals. HPV Types 16, 18, and 31 are 
the major virus associated with cervical cancer. Type 16 is more frequently associated with 
squamous cell histology and type 18 with adenocarcinoma. Other factors associated to the 
increase incidence of the cervical cancer in these patients include, the use of tobacco, 
younger age of first intercourse, higher number of sexual partners, immunosuppression, 
multiple pregnancies, use of hormonal medications, and to a lesser degree family 
antecedents (Molpus &Jone, 2004; Powrie & Cu-Uvin, 2007).   
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2.1.3.2 Clinical manifestation and diagnosis 
Cervical cancer is asymptomatic in its early stage and is most often seen in patients over the 
age of 30 years.  As the cancer progresses some patients may present with non-menstrual 
vaginal bleeding, post coital bleeding, postmenopausal bleeding, pain during the sexual 
intercourse or abnormal vaginal discharges. With more advanced stages of the cancer, the 
presence of back and pelvic pain, bowel and bladder malfunction, lymph nodes 
enlargement or urinary obstruction may be present. Cervical intraepithelial neoplasia (CIN) 
also knows as cervical dysplasia, and invasive stage cancer is diagnosed by histological 
changes, usually based on cytologic examination of the cervical cells. The Pap smear cervical 
cytology is the established screening test to evaluate for dysplasia or cancer.  A single Pap 
smear has a sensitivity of 50% and a specificity of 81% when compared to a biopsy of the 
area. Consecutive Pap smears increase the sensitivity to 99%. In situations where the Pap 
smears suggests an intraepithelial lesion or the presence of carcinoma, a colposcopy and 
directed biopsy is usually diagnostic. Any suspicious visible lesion in this anatomic area 
requires a biopsy. 
2.1.3.3 Therapy 
The management of cervical dysplasia among HIV-infected patients does not differ from the 
general guidelines used for the general population. Observation without specific 
intervention is usually recommended for low degree of cervical dysplasia (CIN 1) unless the 
lesion persists over a period of 18-24 month. If the lesions evolve to a more advanced degree 
of dysplasia, or if there is poor adherence to routine monitoring, immediate intervention is 
necessary. Conventional therapies used for treatment of CIN 2 or 3 dysplasia stage include 
cryotherapy, laser therapy, cone biopsy, and a loop electrosurgical excision procedure 
(LEEP). In patients with CIN 1 that have not been treated with one of the outlined 
interventions, Pap smears or colposcopy should be repeated every 4-6 months to monitor for 
persistence or progression of lesions.  Recurrence rates of 40%-60% after therapy has been 
reported among HIV-1 infected women undergoing these procedures. Very early stage of 
cervical cancer with a depth of invasion of less than 3 mm can be treated with hysterectomy 
or cervical conization.  Lager tumors require radical hysterectomy with pelvic 
lymphadenectomy or pelvic radiation therapy. For advanced stages, therapy with radiation 
or cisplatin-based chemotherapy is indicated in a palliative or neo-adjuvant basis. Since 
recurrence of CIN and cervical cancer after conventional therapy is increased in the HIV-
infected populations, these patients need careful and repeated follow up examinations with 
frequent cytologic screening and colposcopic examination if necessary.   
2.1.3.4 Epidemiology 
Cervical carcinoma is the second most common cause of cancer related mortality in the 
world. The prevalence of this tumor is much higher in countries in which primary and 
secondary prevention strategies are not fully implemented. It is estimated that over 12,800 
new cases are diagnosed annually in the United States with an associated yearly mortality of 
4,600 patients. With the introduction of cervical cytologic screening, the incidence of 
invasive cancer and mortality associated to this condition has decreased dramatically. 
Nevertheless the incidence of cervical carcinoma in HIV infected women (16 per 100.000 
women) continues to be higher than in the general women population (7 per 100,000) in 
United States for the year 2004. Contrary to the other AIDS defining malignancies; the 
incidence of cervical cancer incidence has not changed (RR, 0.8: 95%CI (0.5-1.2) with the 
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introduction of HAART (Bedimo et al.,2004). The standardized incidence ratio (SIR) of 
cervical cancer continues to be significantly higher in HIV infected females when compared 
to the general female population (Simard et al., 2010; Engels et al., 2008; Patel et al., 2008). 
The immunosuppressive effects of the HIV appear to have a lesser role in the pathogenesis 
of this tumor as compared to the oncogenic effects of HPV. The oncogenic effects of HPV are 
not interrupted with HAART, limiting the impact of antiretroviral therapy on the overall 
incidence of cervical cancer in this population of patients. Nevertheless continued 
immunosupression is associated to a more aggressive disease once invasive carcinoma is 
present.   
2.1.3.5 Prevention 
Primary and secondary prevention are essential in order to reduce the incidence of invasive 
cervical carcinoma in HIV infected women. Early detection of dysplastic changes in the 
cervical cells and the use of the recently available HPV vaccine are preventive methods 
directed to reduce the incidence of invasive cancer. HIV infected women need to have a Pap 
smear on initial evaluation and six months after the initial evaluation. If both tests are 
negative then follow up exams every year is suggested.  If there is cervical dysplasia, a 
history of a cervical lesion or if the patient is positive for HPV, the Pap smear should be 
repeated every 4 to 6 months. Some Gynecologists advocate the use of HPV DNA assays as 
a screening modality in HIV infected females to identify women with a higher risk of 
dysplasia. Other assays to detect the HPV mRNA of E6 or E7 protein are also used with 
similar reasons. If a Pap smear demonstrates dysplasia or atypia, colposcopic directed 
biopsy of the cervix is indicated.  HPV vaccine is now available for the active immunization 
against some of the most common HPV oncogenic virus. This vaccine does not immunize 
against all oncogenic HPV viruses, thus repeated screening through Pap smear continue to 
be relevant in the immunized patient. HPV vaccine will provide immunization in females 
prior to the infection, thus the vaccine is recommended prior to sexual activity usually ages 
of 9 and 26 years. The efficacy of the vaccine in inducing an effective immune response in 
the HIV infected host is unknown at this time. Educational interventions on cervical cancer 
along with its relation with HIV and HPV infections need to be reinforced amongst all 
health workers and patients.  
2.2 Non AIDS defining malignancies (HIV-related) 
There are several malignancies that are not AIDS defining, which has a higher prevalence 
amongst HIV infected individuals. These HIV associated malignancies include, Hodgkin’s 
lymphoma, non-small cell lung cancer, head and neck cancer, anal cancer, liver cancer, 
multiple myeloma, and central nervous system malignances (Engels, et al., 2008; Simard et 
al, 2010; Nguyen et al,2010). Most of these malignant conditions can be attributed to 
persistent infection with oncogenic viruses and are not directly associated to the HIV 
induced immunodeficiency. The enhanced life expectancy of HIV infected patients with the 
use of HAART has allowed an increased period of vulnerability where the patients can be 
exposed to oncogenic viruses. An increase in the period of viral latency also accompanies an 
increase in survival. Nevertheless, the immunological deficiency associated to HIV 
contributes to the progressive impairment of cellular immunity against oncogenic viruses 
and virus-infected tumor cells. HIV infection elicits a cytokine deregulation, which disrupts 
the host capacity to control the reactivation and replication of oncogenic viruses, increasing 
the risk of malignant transformation. 
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2.2.1 Hodgkin’s lymphoma 
Hodgkin lymphoma is one of the most common non-AIDS defining malignancy in HIV 
positive patients with an incidence which is 18 times more frequent than in the general 
population.  This lymphoma is characterized by the orderly spread of disease from one 
lymph node group to another and by the present of systemic symptoms. This histology has 
been associated to intravenous drug use, but the occurrence of this lymphoma is not 
exclusively restricted to this risk profile. The diagnosis of Hodgkin lymphoma is usually 
established late in the course of the HIV infection, when patients present a CD4+ T cell 
count of 300 cells per mm3 or less. 
2.2.1.1 Pathophysiology  
The histology presentation of Hodgkin lymphoma among HIV positive patients tends to be 
more unfavorable as compared to the general population. The mixed cellularity and the 
lymphocyte-depleted histology subtypes are more frequently found in HIV infected persons 
when compared to the general population. Contrary, the nodular sclerosis type is less 
frequent in HIV persons. The general population with Hodgkin lymphoma demonstrates 
tumor with an extensive infiltrate of T lymphocytes as compared with the HIV patient in 
which the malignant cellular infiltrate is substantially depleted of T lymphocytes. These 
variations in histology convey a more aggressive course for the Hodgkin lymphoma in HIV 
infected patient.  Epstein Barr virus (EBV) is associated with Hodgkin lymphoma, and may 
play an important role in the pathogenesis of this disorder since 80%-90% of patients with 
HIV related Hodgkin lymphoma have EBV genome integrated within Reed-Sternberg cells 
(RSC). This proportion is higher than the one detected in the general population. The RSCs 
are the malignant cells seen in Hodgkin lymphoma and their presence is essential for the 
diagnosis of this disorder.  The survival of the RSC depends on the antiapoptotic nuclear 
factor (NF) қB pathways. The activation of this pathway relies on the recruitment of 
inflammatory cells to the tumor mileu, which provide essential signals that stimulates the 
proliferation and inhibits the apoptosis of the RSC. In advanced AIDS stages, the incidence 
of Hodgkin lymphoma may decrease due to inability of the tumor mileu to recruit 
lymphocytes and other inflammatory cells essential for the survival of the RSC.  The latent 
expression of EBV-associated transforming protein on the surface of the RSC may also help 
the proliferation of malignant cells. This latent protein mimics the activated CD40 receptor 
and allows the constitutive activation of the NF қB pathways, resulting in inhibition of the 
RSC apoptosis. Thus EBV can potentially promote oncogenesis independent of the availability 
of inflammatory and activated CD4 T cells. The nodular sclerosing histology appears to be less 
associated to EBV infection and is more likely to be seen in patients with a higher CD4 cell 
count.  All patients with Hodgkin lymphoma require complete staging with total body 
imaging studies and bone marrow examinations (Portlock & Yahalom, 2004; Doweiko, 2007b). 
2.2.1.2 Clinical manifestation and diagnosis 
The clinical manifestations of Hodgkin lymphoma in HIV infected patients differ from the 
presentation seen in the general population. HIV associated Hodgkin lymphoma is more 
aggressive in nature, usually presents in advanced stages of the disease with more than 75% 
having stage III or IV at diagnosis. Liver and spleen involvement is seen in 65% of patients 
and bone marrow involvement in 50%. More than 80% of these patients present 
constitutional symptoms such as unexplained fever, night sweats, or significant weight loss. 
The overall survival of HIV related Hodgkin lymphoma prior to the introduction of HAART 
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was around 18 months. This high mortality was associated to an increased vulnerability of 
infections after systemic chemotherapy and the short disease free interval often associated 
with this cancer. The introduction of HAART has improved the survival of patients with 
HIV  related Hodgkin lymphoma, decreasing the incidence of opportunistic infections, and 
allowing greater tolerance to the antineoplastic drugs.  
2.2.1.3 Therapy 
The therapy of Hodgkin lymphoma depends of the stage of disease at initial presentation.  
The therapy of this lymphoma is multidisciplinary in nature with external beam radiation 
therapy, chemotherapy or a combination of both. Surgical interventions have a limited role. 
Radiation therapy or chemotherapy is an effective treatment for stage I and II of the 
Hodgkin lymphoma. For more advanced stages, the use of combination chemotherapy with 
the ABVD regimen (adriamycin, bleomycin, vinblastine and dacarbazine) along with 
involved field radiation in selected patients is recommended. A rate of 80% of complete 
remission is associated with this regimen. 
2.2.1.4 Epidemiology 
Hodgkin’s lymphoma accounts for less than 1% of all the tumors in the US and is more 
common in men than in women. There are two incidence peaks between the ages of 15 to 34 
and in those over the age of 55 years. Hereditary factors, infection with Epstein-Barr virus, 
and T-lymphocyte immune dysfunction, are associated with this type of cancer. The risk for 
Hodgkin’s lymphoma is significantly higher in the HIV/AIDS population with a 
standardized incidence rates between 5.6 and 16.2 in relation to the general population 
(Grulich et al., 2007). This type of lymphoma has a more aggressive debut in HIV infected 
persons, than in the general population. When evaluating the effect of antiretroviral 
therapies in the incidence of Hodgkin’s lymphoma a great majority of the studies reported a 
significant increment of this type of cancer in the HIV population after the availability of 
HAART (Bedimo et al., 2004). Standardized incidence rates of Hodgkin’s lymphoma that in 
the pre HAART era was around 2.0 increased beyond 6.0 in the HAART era (Simard et al, 
2010; Engels et al., 2008).  
2.2.1.5 Prevention 
There are not specific measures to prevent this type of lymphoma. 
2.2.2 Lung cancer  
Lung cancer is one of the most frequent tumors seen in the general population and is the 
leading cause of cancer related mortality in the United States. Around 90% of the genesis of 
this neoplasm is directly associated to the use of tobacco. Passive smokers have a small but 
significant risk of developing lung cancer when compared to non-smoking population 
(Miller, 2004). Other risk factors for lung cancer include a genetic predisposition, exposure 
to environmental toxins, the presence of chronic pulmonary infections, and the presence of 
an immunosuppressive state. This later risk factor has been confirmed in the organ 
transplanted populations of patients, which require prolonged use of immunosuppressant 
therapy (Grulich et al., 2007). The incidence of lung cancer is increased in HIV infected 
individuals and is often diagnosed in younger age individuals with a history of smoking. 
The implementation of HAART has not resulted in a significant change in the lung cancer 
incidence in these patients (Bonnet & Chene, 2008).  
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2.2.2.1 Pathophysiology 
The majority of malignant tumors of the lung originate from the bronchial epithelium. These 
bronchogenic carcinomas are histologically divided into small cell lung cancers and non-
small cell lung cancers. The non-small cell lung cancers are subdivided into 
adenocarcinoma, squamous cell carcinoma and large cell carcinoma.  The adenocarcinoma is 
the most frequent histological subtype found in HIV infected patients. The presence of small 
cell lung cancers tends to be less common in HIV infected persons. The management of 
small cell lung cancers is generally chemotherapy and for early stages of non-small cell lung 
cancers, the use of surgery or radiotherapy is usually employed. The process of malignant 
transformation towards lung cancer is associated to a multistep accumulation of genetic 
mutations, which regulate growth, and apoptosis of the respiratory epithelium. 
Premalignant lesions including squamous dysplasia and atypical alveolar hyperplasia have 
been associated with some chromosomal mutations including chromosomes 3p, 2p, and 9p. 
Bronchogenic carcinomas have been related to alterations in chromosomes 3p, 5q, 9p, 11p, 
13q and 17P. The majority of the genetic alterations in these tumors involve deletions of 
tumor suppressor genes that are essential for the proliferation of tumor cells. Other than 
genetic mutations, an increase in cellular proliferation may be the result of autocrine growth 
through factors that include neuropeptide growth factors, insulin like growth factors, 
transforming growth factor alpha, stem cell growth factor, and heregulins.  The precise 
mechanisms behind the increased incidence of HIV associated lung cancer remains 
unknown. Immunological damage induced by the virus, pulmonary epithelium damage 
induced by recurrent infections, the use of tobacco and other drugs are synergistic factors 
which could contribute to the development of this cancer in the HIV population. 
2.2.2.2 Clinical manifestation and diagnosis 
Lung cancer is usually asymptomatic when it is detected in its early stages. It is not unusual 
to have an abnormal routine chest radiograph as the initial test, which leads to the 
diagnosis.  In late stages the presence of pulmonary related symptoms is common. Common 
symptoms and findings in these patients include cough, changes in frequency and intensity 
of a chronic cough, hemoptysis, airways obstruction, chest pain, disnea, postobstructive 
pneumonia, fever and pleural effusion. Symptoms related to direct organ invasion to the 
heart, great vessels of the upper mediastinum, brain, bone, adrenal glands and liver may be 
present (Miller, 2004).  In metastatic cancer, cervical and supraclavicular lymphadenopathy 
may be present. HIV associated lung cancer is usually diagnosed in the late stages and as a 
consequence is associated to a worse prognosis (James, 2006). A diagnosis of lung cancer can 
be made by examination of sputum cytology or histological evaluation of tissue biopsy. 
Positron- emission tomography scanning or contrast nodule enhancement CT is occasionally 
used as a non-invasive alternative to discriminate between a malignant and a non-malignant 
pulmonary lesion. This technique is associated to a high number of false negative and false 
positive results. 
2.2.2.3 Therapy 
Surgery is the most appropriate treatment in non-small cell lung cancer for patients that 
have potentially resectable disease. It is imperative that patients in whom a pulmonary 
resection is being considered, the baseline pulmonary function tests are adequate to tolerate 
the resection and that the general medical condition is optimal to minimize surgical 
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complications. Immunological status is not a very important prognostic variable to preclude 
surgical cure for these patients.  Radiation therapy is also an effective treatment for the non-
small cell lung cancer, especially when combined with chemotherapy. In advanced stages of 
the disease, palliative chemotherapy in the form of cisplatin, carboplatin, paclitaxel, 
mitomycin, vinca alkaloids, gemcitabine, vinorelbine, ifosfamide and etoside may be used. 
The therapeutic interventions available for HIV positive patients are similar to their HIV 
negative counterparts.  
2.2.2.4 Epidemiology 
Lung cancer is one of the most frequent tumors in the US and is the leading cause of cancer 
related mortality. In 2007, the incidence in the United States was of 65.5 per 100,000. Lung 
cancer is the most frequent non- AIDS defining tumor in the HIV infected patient.  The 
standardized incidence ratio (SIR) of this tumor is higher in the HIV infected population, as 
compared to the general population (Simard et al., 2010; Engels et al., 2008; Bonnet et al., 
2008; Patel et al., 2008).  The impact of HAART in modifying the incidence of the HIV 
associated lung cancer is minimal.  Engel et al. has reported that the SIR for the lung cancer 
before and after HAART therapy remains 2.6 in their study cohort (Engels et al., 2006). 
2.2.2.5 Prevention 
The predominant intervention, which will reduce the incidence and prevalence of lung 
cancer in the HIV infected population, is the avoidance or reduction in tobacco exposition. It 
is highly recommended that non-smokers remain free of tobacco and that smokers reduce or 
cease tobacco use. This recommendation continues to be relevant even in the group in with a 
diagnosis of lung cancer has been established.  In addition HIV infected persons need 
remain compliant with their HIV therapy in order to reduce the likelihood of recurrent 
pneumonia and other respiratory complications associated to HIV. 
2.2.3 Hepatocelullar carcinoma 
Hepatocellular carcinoma is the most common primary liver cancer, with an estimated 
incidence of 500,000 worldwide cases per year. It is more common in men and more 
frequently seen between the ages of 50 and 60 years old. Hepatocellular carcinoma is the 
third leading cause of cancer mortality worldwide. The incidence rates of this carcinoma in 
United States have historically been lower as compared to other tumors; nevertheless it has 
doubled in the past decades. In addition the trends of mortality associated to this tumor 
have increased at a faster rate than most other tumors of the body. Hepatocellular carcinoma 
often arises in the setting of a damaged liver, as seen in liver cirrhosis. As a consequence the 
risk factors for hepatic cirrhosis are also risk factors for this cancer. The most common 
external agents responsible for hepatic cirrhosis include prolonged abuse of alcohol, and 
chronic infection with the Hepatitis virus type B (HBV) and C (HCV) virus. The coexistence 
of HIV and HCV infection has been associated to a synergistic damage to the liver leading to 
a higher incidence of this liver cancer. The incidence of Hepatocellular carcinoma in HIV 
infected persons has increased with the introduction of HAART. With the growing 
armamentarium of anti retroviral interventions available for these patients, the survival and 
quality of life have markedly improved. This survival improvement has permitted re-
exposition or continued expositions to drugs, alcohol, tobacco and viral agents, which will 
compound the extent of liver tissue damage in this high-risk population.  
www.intechopen.com
 
HIV/AIDS Associated Malignant Disorders: Role of Highly Active Antiretroviral Therapy 
 
447 
2.2.3.1 Pathophysiology  
Hepatocellular carcinoma is an epithelial tumor that arises from the malignant 
transformation of the hepatocyte. In the majority of patients the tumor originates in the 
background of a cirrhotic liver suggesting the need of a damaged liver for the malignant 
transformation to occur.  As a consequence all conditions, which lead to hepatic cirrhosis, 
increase the risk of this carcinoma. The conditions, which are considered risky factors for 
hepatic cirrhosis, include chronic HBV or HCV infections, chronic alcohol abuse, 
hemochromatosis, sialohepatitis, certain congenital hepatic disorders, and exposure to 
hepatotoxic agents. There are exceptional cases in which Hepatocellular carcinoma develops 
in the absence of liver damage. The exact mechanism for the genesis of this malignancy is 
uncertain in many of the scenarios described.  In patients with chronic HBV infection, the 
integration of the HBV DNA into the hepatocyte genome produces a significant disturbance 
in the host tumor suppressor genes and an activation of oncogenes. This leads to a 
disruption in the cell’s cycle, inhibition of the DNA repair mechanisms, and inhibition of 
hepatocyte apoptosis. These mechanisms contribute to the malignant transformation and 
tumor proliferation.  In chronic HCV infection, immune mediated inflammation is present 
which results in inhibition of hepatocyte apoptosis. It has been postulated that the co-
existence of HBV, HCV and HIV infection produces a significant increment in the risk in 
developing Hepatocellular carcinoma. These co-infections have also been associated with a 
reduction in the therapeutic efficacy for HBV and HCV, resulting in continued active co-
infection with an augmentation in the incidence and the progression of this neoplasm 
(Fallon et al., 2006; McDonald et al., 2008).  
2.2.3.2 Clinical manifestation and diagnosis 
Hepatocelullar carcinoma usually presents with pain in the right upper quadrant of the 
abdomen, jaundice and hepatomegaly. Constitutional symptoms may include, fever, early 
satiety, lost of weight and anorexia. Occasionally some patients may present with hepatic 
function decompensation causing ascites, lower extremity edema, esophageal varices 
bleeding, acute portal hypertension, and encephalopathy. Laboratory findings related to 
liver failure may be present including elevated levels of alkaline phosphatase, total 
bilirubin, ALT or AST. The presences of an elevated α-Fetoprotein or des-gamma 
carboxyprothrombin are markers for the presence of the liver carcimoma and may be used 
as measures of tumor growth. Ultra sound (US), three-phase tomography (CT) or magnetic 
resonance imaging (MRI) is the imaging techniques that suggest the presence of this 
neoplasm. Histological evaluation of the hepatic mass is often used to confirm the 
diagnosis. Current guidelines suggest that in the presence of an elevated level of α-
Fetorprotein and the presence of a hepatic mass in the context of a cirrhotic liver, a 
confirmatory biopsy is not necessary. Tissue confirmation is recommended for cases 
without elevated level of α-Fetorprotein or if the diagnosis remains uncertain (Fallon et 
al., 2006; McDonald et al., 2008). 
2.2.3.3 Therapy 
The prognosis of the Hepatocelullar carcinoma is variable and it largely depends whether 
complete surgical resection of the tumor is possible. Effective surgical interventions are 
compromised when the primary tumor is large, if there is vascular involvement, if the 
tumor infiltrates both hepatic lobes, and if there is evidence of metastatic disease. In 
addition, poor residual hepatic function may prevent hepatic resection. It is estimated that 
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less than 15% of the patients with this cancer are surgical candidates and of these 60% have 
a tumor recurrence. Additional therapeutic interventions, which may be appropriate, 
include liver transplantation, hepatic chemoembolization, intratumoral injection of ethanol, 
and radiofrequency ablation. Hepatic transplantation is performed in patients with 
Hepatocelullar carcinoma without metastasis, which fulfills the Milan criteria. Systemic 
therapy with one of the tyrosine kinase receptor inhibitors such as sorafenid or sunitinib 
may be used. These therapies are not considered curative in nature but will increase 
survival (Fallon et al., 2006; McDonald et al., 2008).  
2.2.3.4 Epidemiology 
Hepatocelullar carcinoma is the fourth more common malignant tumor in men and the sixth 
most common in females in the United States.  It is the third leading cause of cancer 
mortality worldwide. The incidence of Hepatocelullar carcinoma in HIV infected patients is 
higher than in the general population in great measure related to the common transmission 
related practices shared between HIV with HBV and HCV. Co-infected patients have been 
reported to present with more advanced Hepatocelullar carcinoma, and have a higher 
mortality as compared with patients who are HIV negative. The introduction of HAART has 
improved the life expectancy among HIV positive individuals but has allowed a greater risk 
for exposure to additional agents with oncogenic potential. In the HIV/AIDS Cancer Match 
Study of Simard and collaborators an increment in incidence of Hepatocelullar carcinoma of 
90% (RR, 1.9: 95% CI, 0.9%-3.92%) was seen when comparing the pre HAART with the post 
HAART era (Simard et al., 2010). Other studies have confirmed this evolving increasing 
trend in the incidence and prevalence of this malignancy across time in different 
populations (Engels et al., 2008; Mayor et al., 2008b). Furthermore, the standardized 
incidence ratio (SIR) of Hepatocelullar carcinoma is significantly higher in the HIV infected 
patient as compared to the general population (Simard et al., 2010).  
2.2.3.5 Prevention 
The pathogenesis of Hepatocelullar carcinoma is intimately associated to alcohol abuse and 
chronic infection with HBV and HCV. Primary, secondary and tertiary preventive measures 
that reduce the risk for exposure to these agents or viruses will directly and indirectly 
reduce the incidence of this cancer. This is particularly true in the higher risk groups such as 
those with HIV infection. It has been shown that patients with HIV infection have high-risk 
practices that predispose them to co-infection with hepatitis A (HAV), HBV, and HCV. In 
addition alcohol abuse continues to be common practice in these patients. HAV infection 
carries a predominant fecal-oral viral transmission route that involucrate more commonly 
men who have sex with men and injecting drug users; HBV infection is predominantly 
transmitted by percutaneous or mucous contact with infected blood or body fluids  
including semen and saliva. HIV associated risk groups such as men who have sex with 
men, high risk heterosexual contact, or injecting drug use are the predominant group with 
this risk factor. Lastly, HCV infection is transmitted principally by percutaneous contact 
with infected blood, and this is a relevant issue in HIV patients who are injecting drug use 
(Samet, 2007) or who received transfusions of unscreened blood. Most patients with acute 
HBV or HCV infection are asymptomatic and early diagnosis rarely occurs. Approximately 
4 % of the HBV mono-infected persons and 20% co-infected with HIV will develop chronic 
liver disease. Over 80% of HCV infected individuals will eventually develop chronic hepatic 
disease. In the majority of patients with either infection, the process will remain 
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asymptomatic and undetected many years prior to the onset of liver damage and the 
development of cancer. All patients infected with HIV should undergo screening testing for 
HAV, HBV and HCV.  In patients who are positive for the HCV serology and in those with 
unexplained liver disease determination of HCV virus load is suggested. Repeated testing 
after 4 months of follow up may be required in some cases if the infection was recently 
adquired. If high risk behaviors persist after an initial negative screening test, repeat testing 
on an annual basis is recommended. There is no HCV vaccine available. In patients where 
HBV infection is suspected, determination for the presence of the multiple viral components 
and antibodies in the serum is recommended. If the surface antigen (HBsAg) and the surface 
antibody (HBsAb) are negative, then vaccination against the HBV is suggested. This is 
particularly relevant for the HIV infected individual since the risk for HBV is high in this 
group. In individuals with detectable HBsAg, detectable HBsAb, or with elevated serum 
liver enzymes levels, the determination of the HBV viral load needs to be done. Chronic 
inactive viral infection is determined when the antibodies are positive and the viral load is 
negative. Both HCV and HBV require opportune therapy in order to minimize the extent of 
liver damage. HCV chronic infection is treated principally by the combination of peg 
interferon alpha and Ribavirin. Chronic HBV infection is treated with antiviral agents such 
as Lamivudine (3TC), Ettricitabine (FTC), Adefovir or Tenofovir.  HIV co-infected persons 
on ART need to be monitored with liver function tests, since concomitant ART could cause 
liver damage and be responsible for metabolic disorders when used in combination with 
other medications.   
Counseling and educational interventions directed to reduce the risk behavior associated to 
HBV, HCV and HIV transmission play an important role in Hepatocelullar carcinoma 
prevention (Center for Disease Control, 2001). One example of an intervention used in our 
cohort was a multimedia educational intervention, which was validated in Hispanic HIV 
injecting drug users in Puerto Rico (Mayor el al., 2010). This intervention motivated the 
participant to abolish their risky behaviors practices when injecting drugs. The Health Belief 
Model and Social Cognitive Theory were used as theoretical framework to modify the 
decision making process that led to the avoidance, or reduction of the risk factors relevant 
for acquiring new HCV infection (Mayor et al., 2008a). We are planning to extend this 
intervention to patients who are at an early stage of drug addiction in order to capture a 
larger cohort of patients who have not been infected with HBV or HCV. Counseling and 
educational interventions regarding alcohol use and abuse is an important approach 
particularly in the HIV infected person who has a high prevalence of both drug and alcohol 
use and abuse. 
2.2.4 Squamous cell cancer of the anus 
Squamous cell carcinoma of the anus is a tumor that originates from the epidermal cells of 
the hair bearing perianal skin. This tumor may develop outside and beyond the anal verge.  
The tumor is responsible for 3% of the malignancies of the lower gastrointestinal tract. It is 
intimately associated to infections with one of the carcinogenic types of HPV.  The majority 
of patients with this tumor had anal intercourse as HIV risk factors, especially in the MSM 
group (Davis, 2008; Doweiko, 2007a; National Institute of Health, 2011).  
2.2.4.1 Pathophysiology  
Quite similar in pathogenesis to uterine cervix neoplasias, HPV infection has an important 
role in the genesis of the anal dysplasia or anal intraepithelial neoplasia (AIN) and its 
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progression to squamous cell cancer. HPV is the most common sexually transmitted 
infection in the United Sates. The incidence of HPV infection is high and there is evidence of 
an increasing prevalence of infection in the HIV infected group of patients. HIV associated 
risk factor of MSM is associated to a high prevalence of anal HPV infection and at higher 
risk of developing anal cancer. The degree of anal dysplasia is inversely correlated with 
CD4+ T lymphocyte count, suggesting an important role of the immune system in 
controlling the impact of HPV infection. With improvement in survival associated to 
HAART, the latency period for HPV infection has also increased, incrementing the risk of 
malignant transformation of the dysplastic tissue. Anal squamous cell cancer has a more 
aggressive presentation and clinical course in HIV infected persons when compared to HIV 
negative individuals. Other risk factors for the development of anal dysplasia include, 
heavy cigarette smoking, anal intercourse, and a greater number of lifetime sexual partners. 
These factors have all been associated to the increasing incidence of the anal cancer in men 
and in women across the world (Daling et al., 2004). 
2.2.4.2 Clinical manifestations and diagnosis 
Dysplasia of the squamous epithelium of the anus is a silent condition that becomes 
symptomatic as it evolves to the malignant stage. Anal carcinoma can induce changes in the 
intestinal habits, rectal bleeding, rectal itching, rectal irritation or the presence of lumps in 
the anal area. Low back pain and vaginal symptoms could be also part of the symptoms 
associated to these processes. In advanced stages the malignant process could ulcerate and 
infiltrate the anal sphincter muscle, incrementing the magnitude of the symptoms. A 
disruption of the integrity of the anal mucosa seen in these tumors may predispose to the 
development of infections in this area. The presence of anal dysplasia and invasive 
carcinoma require pathologic confirmation. The anal Pap smear is a screening test to 
evaluate cytologic changes in the anal epithelium in high-risk persons.  High-resolution 
anoscopy (HRA) should be considered if the anal Pap smear shows atypical cytology and 
should be performed in patients who have low or high grade squamous intraepithelial 
lesions. Visible lesions should be biopsied to determine the magnitude of the histological 
changes and to rule out invasive cancer.  
2.2.4.3 Therapy 
Localized dysplasia requires clinical follow-up with anoscopy and colposcopic biopsy every 
4 to 6 months.  Lesions can be removed with photocoagulation. Frank carcinoma should be 
managed with surgical excision or a combination of chemotherapy with concomitant 
radiotherapy. Chemotherapy with 5-fluorouracil, mitomycin-C, platinum and other 
analogues has been used with success, particularly for early stage tumors. This modality 
will preserve anal sphincter function in the majority of patients. More advanced tumors will 
require an abdomino/perineal tumor resection with the placement of a permanent 
colostomy. 
2.2.4.4 Epidemiology 
Prior to the HIV epidemic, the presence of carcinoma of the anus was seen in the older 
patient, particularly women. With the onset of HIV infection in the community, anal 
carcinoma is detected in younger patients, and very often associated to HPV infection. 
Anogenital dysplasia and anal carcinoma are more frequently associated with HPV types 16, 
18, 31, 33 and 35.  Similar to other tumors influenced by external agents such as viruses, the 
incidence of anal carcinoma has increased significantly in the HAART era (Simard et al., 
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2010; Engels et al., 2008; Long et al., 2008).  Simard and coauthors in their United States 
HIV/AIDS Cancer Matched Study reported a 190% increment in the incidence of anal 
carcinoma (RR, 2.9: 95% CI, 2.1%-4.0%) in the HAART era when compared to pre HAART 
era. HAART associated increments in the survival of HIV infected patients will also prolong 
the HPV carcinogenic effects over the anal epithelium leading to an increased incidence of 
malignant transformation.   
2.2.4.5 Prevention 
Although formal guidelines recommending anal Pap smear screening have not been 
adopted, it is clear that anal cytologic screening for HIV-infected men and women at risk of 
HPV infection or with anogenital warts is warranted. Follow up exams are mandatory for 
patients with anal dysplasia, or history of anal cancer.  Risk reduction education and 
intervention in sexual and smoking behaviors could have an indirect effect in the prevention 
of the anal cancer. 
2.2.5 Oral cavity/pharynx cancer 
The malignant processes of the cavities of the head and neck have different histological 
types.  In this discussion we are reviewing the data associated to squamous cell carcinoma 
of the oropharyngeal tract. Other important histologies cancers of the oral cavity and 
pharynx, such as lymphomas, sarcomas, thyroid tumors and benign tumors are not 
addressed in this section.  The squamous cell carcinomas, which originate in the oral cavity, 
oropharynx, hypopharynx, and larynx are strongly associated to the use of tobacco. The 
tobacco may be inhaled in several forms such as cigarettes or cigars, or it may be smokeless 
such as chewing tobacco or snuff. Tumors localized in the oropharynx may also be 
vinculated to infection with HPV (Posner, 2004). As anticipated the incidence of 
oropharyngeal cancer is higher in the HIV infected patient as compared to the general 
population and the incidence of this tumor is higher in the post HAART era.  
2.2.5.1 Pathophysiology 
Tobacco use in any form, alcohol consumption, HPV infection, a weakened immune system, 
micronutrient deficiencies, and poor oral hygiene have all been implicated in the 
pathogenesis of head and neck neoplasms (Kreimer et al.,2004; Marur et al., 2010; Posner, 
2004, National Institute of Health, 2005).  Smoking produces a direct exposure of the oral 
and pharynx mucosa to nicotine and other carcinogenic components of the tobacco, which 
increase the risk of squamous cell proliferation. Frequent and heavy consumption of alcohol 
produces local and systemic carcinogenic effect over the mucosa. It is well established the 
synergism associated between the use of alcohol and tobacco abuse and the risk of head and 
neck tumors. Infection with HPV types 16 has also been implicated in oropharyngeal 
tumors.  The exact mechanism of HPV associated tumor transformation is unclear. It is 
postulated that HPV induces the inactivation of tumor suppressor proteins or genes, which 
promote cell immortality and dedifferentiation.  HPV infection is very common and 
widespread in HIV infected patients.  Damage of the HIV individuals’ immune integrity 
may enhance the tissue susceptibility induced by HPV.  
2.2.5.2 Clinical manifestations and diagnosis 
The clinical manifestation are varied and related to the location and stage of the tumor. 
Lumps, masses, ulcers may be present in the oral cavity. Problems with swallowing, 
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bleeding or pain may be some of the symptoms. There may be restrictions in the movement 
of the tongue, or difficulty swallowing certain products. Other manifestations my include, 
loose tooth, pain in the different bone structures of the face, difficulties with visual acuity, 
hoarseness, and lymph node enlargement. A diagnosis should be suspected on the basis of 
the clinical manifestations, physical examination of the head and neck region, endoscopy, 
computer tomography (CT) scan, magnetic resonance imaging (MRI), positron-emission 
tomography (PET). Histological confirmation with a needle aspiration and biopsy or 
excisional biopsy needs to be done. Complete staging of the tumor should follow a 
histological diagnosis (Posner, 2004).  
2.2.5.3 Therapy 
The management of these cancers is varied and may include surgery, radiotherapy, 
chemotherapy, neoadjuvant-chemotherapy, chemo-radiotherapy, and combination-
modality interventions. Nutritional support to prevent significant weight loss is important. 
Associated morbidities such as lung, heart or liver dysfunction need to be identified in order 
to modify the cancer therapy to be instituted. Speech rehabilitation is occasionally required. 
Lifelong follow-up is suggested.  
2.2.5.4 Epidemiology 
Head and neck cancers account for 3 to 5% of all the tumors diagnosed in the United States. 
It is the sixth most common cancer worldwide. About 40,000 new cases are detected 
annually. The majority (95%) are squamous cell carcinomas with the oropharynx 
representing the most common anatomic site (Posner, 2004). These cancers are three times 
more common in men with a peak incidence over the age of 50 years of age.  Approximately 
13,000 deaths are attributable each year to these cancers.  The patient with HIV infection is at 
a higher risk for oropharyngeal cancer with a SIR between 2.1 and 5.6 (Grulich et al., 2007; 
Patel et al., 2008).  As with the other HPV related cancers, the impact of HAART in the 
natural history of these tumors remains unclear.  Engels and co-authors have reported a 
decline in the rates of HIV associated oropharyngeal cancer with the introduction of 
HAART showing a reduction of the standardized incidence ratio (SIR) from 2.5 to 1.5. 
Nevertheless the risk of HIV associated head and neck cancer is higher as compared to the 
general population (Simard et al., 2010; Engels et al., 2008).  
2.2.5.5 Prevention 
There is no approved test for the early detection of oral cavity/pharynx cancers. 
Consequently the prevention of these tumors rests on improving the risky behavior patterns 
of patients. Smoking and alcohol abuse avoidance and cessation are the most important 
prevention measure for this type of cancer. Up today there is not an effective prevention 
protocol for HPV in relation to oropharynx cancer. Having a faithful relation with one 
person, limiting the number of sex partners, having a partner who did not have o had few 
sex partners, could limit the probability of HPV infection, but not eliminate it.  
3. Conclusion 
The use of HAART for patients with HIV infection has led to a partial restoration of the 
immune system prolonging the survival of these patients. The success of this therapy has 
dramatically altered the natural history and clinical course of infection. HIV/AIDS has 
become a chronic disease with the co-existence of co-morbid conditions, which have an 
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important effect on the health of these patients. An increased likelihood of exposure to 
cancer promoters such as oncogenic viruses, increments in the exposure to tobacco and 
alcohol and continued risky practices have had a major role in the increased risk of 
developing malignant conditions in these patients. The incidence of most of the AIDS 
defining malignancies have decreased in large part due to immune restoration present in 
many patients. However, the incidence of other tumors such as uterine cervical cancers, 
Hodgkin’s lymphoma, certain non-Hodgkins lymphomas, HPV related cancers, lung cancer, 
and liver cancer have all seen an increase in the HAART era. The synergistic effects of 
tobacco use, alcohol use, dietary elements and viral co-infections are having an effect in the 
malignant transformation of tissues in the HIV infected patient. Consequently, an 
appropriate and opportune management of the HIV infection needs to be supplemented 
with cancer preventive strategies in this high-risk group of patients. Implementation of 
recommended cancer screening techniques, educational intervention, and relevant 
vaccination in the HIV infected populations should decreased the morbidity and mortality 
rate of HIV associated malignancies. Furthermore, adequate and opportune cancer 
prevention efforts would be cost effective in the management of this high risk population. 
Researches into the barriers present, which are obstacles to the implementation of these 
important prevention techniques, are very relevant and require further evaluation.  
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